Commercialization and strategic partnerships for regulated healthcare growth.
Q22 supports healthcare organizations with commercial execution, market adoption and strategic growth in complex regulated environments.
Led by Ivo Schefman, senior commercial healthcare leader with 20+ years across MedTech, Pharma, market access, EU GMP healthcare ventures and international strategic partnerships.
Commercial execution where healthcare becomes complex.
Q22 is not a broad consultancy proposition. The focus is commercialization, strategic partnerships and growth within regulated healthcare markets.
Commercialization
Market adoption, go-to-market choices, value proposition, commercial structure and execution.
→Strategic partnerships
Licensing, commercial agreements, alliance development and stakeholder alignment.
→Strategic accounts
Senior commercial approach for key accounts, stakeholders, tenders and growth.
→European growth
Market access, partner selection, local commercial setup and regulated expansion.
→Healthcare ventures
From venture build-up to financing, partner strategy and commercial validation.
→Proof from regulated healthcare environments.
Q22’s value comes from actual commercial accountability, not advisory frameworks.
Senior operator, available for selective advisory and growth engagements.
Q22 is the advisory practice of Ivo Schefman. The positioning is deliberately focused: commercial growth, strategic partnerships and commercialization across MedTech, Pharma, CDMO and regulated healthcare.
Discuss commercialization, partnerships or regulated healthcare growth.
For organizations that need senior commercial execution across MedTech, Pharma, CDMO or healthcare.
Contact